Prof. Wu Yi-Long (吴一龙) - Pioneer of Lung Cancer Targeted Therapy & Director of Guangdong Lung Cancer Institute

About Prof. Wu Yi-Long

Prof. Wu Yi-Long (吴一龙) is one of the most influential thoracic oncologists and clinical researchers in the world, serving as Chief Physician, Professor, Doctoral Supervisor, and Director of the Guangdong Lung Cancer Institute (GLCI) at Guangdong Provincial People's Hospital (GDPH) in Guangzhou. Widely recognized as the father of lung cancer targeted therapy in China, Prof. Wu has dedicated over four decades to revolutionizing the treatment paradigm for thoracic malignancies, transforming lung cancer from an untreatable disease into a manageable chronic condition for millions of patients globally.

Prof. Wu stands among an elite group of international physician-scientists who have repeatedly published landmark, practice-changing Phase III clinical trials in the New England Journal of Medicine (NEJM). As the founder and leader of the Chinese Thoracic Oncology Group (CTONG), his pioneering clinical trials and translational genomic research have directly shaped international guidelines (including NCCN, ESMO, and CSCO) and established China as a global powerhouse in precision oncology.

Core Clinical Specializations & Precision Oncology Innovations

1. Lifelong Whole-Course Precision Management of Lung Cancer

Prof. Wu pioneered the philosophy of "whole-course management" (全程管理) for non-small cell lung cancer (NSCLC). Rather than relying on isolated lines of therapy, his approach maps out a dynamic, multi-year treatment blueprint from initial presentation through subsequent progression events. By integrating continuous molecular tracking, localized ablative interventions for oligometastatic lesions, and rational sequence planning, his patients consistently achieve survival outcomes that rank among the highest worldwide.

2. Rare Driver Gene Mutations & Emerging Targets (RET, MET, HER2, KRAS, ROS1)

While classical mutations such as EGFR and ALK have well-established targeted regimens, rare oncogenic alterations historically posed immense clinical hurdles. Prof. Wu has led global breakthroughs addressing these complex targets:

• Adjuvant RET-Inhibited Therapy (LIBRETTO-432 in NEJM): In May 2026, Prof. Wu published the definitive results of the global multicenter Phase III LIBRETTO-432 trial in the New England Journal of Medicine, establishing selpercatinib as the world's first proven post-surgical targeted adjuvant therapy for early-stage RET fusion-positive NSCLC, closing a major historical gap in curative thoracic oncology.
• MET Amplification & Exon 14 Skipping (KUNPENG in Lancet Oncology): In 2025, Prof. Wu published the pivotal KUNPENG trial in The Lancet Oncology, establishing bozitinib (伯瑞替尼) as a potent, highly selective therapy for advanced NSCLC harboring MET alterations.
• Comprehensive Rare Mutation Coverage: His clinic provides authoritative management for HER2 insertions, ROS1 fusions, KRAS G12C/G12D mutations, and NTRK gene fusions, offering tailored solutions when standard therapies are ineffective.

3. Minimal Residual Disease (MRD) & Dynamic Liquid Biopsy

Prof. Wu is a global authority on using circulating tumor DNA (ctDNA) for Minimal Residual Disease (MRD) surveillance. Following curative lung cancer resection, dynamic ultra-deep ctDNA monitoring distinguishes patients who are biologically cured from those harboring microscopic residual disease. This precision strategy spares low-risk patients from unnecessary, debilitating adjuvant chemotherapy while intensifying targeted interventions precisely when molecular relapse is first detected—months before anatomical lesions appear on radiographic CT scans.

4. Pioneering the "Drug Holiday" Strategy in Advanced Disease

In a landmark original clinical investigation published in JAMA Oncology in 2024, Prof. Wu and his team introduced the innovative concept of structured "drug holidays" (treatment-free intervals) for selected advanced NSCLC patients exhibiting deep, sustained molecular responses to targeted therapy. This groundbreaking paradigm minimizes cumulative toxicities, reduces financial burden, prevents premature clonal resistance, and dramatically restores patients' day-to-day quality of life.

Academic Leadership, Global Trials & Landmark Publications

Prof. Wu Yi-Long's scientific bibliography represents one of the most referenced and respected bodies of oncology research globally:

• Pinnacle Medical Publications: Prof. Wu has repeatedly authored landmark articles in the world's top medical journals, including multiple primary publications in The New England Journal of Medicine (NEJM), The Lancet Oncology, Journal of Clinical Oncology (JCO), JAMA Oncology, and Cancer Cell.
• Redefining Global Guidelines: His clinical trial data have served as the foundation for FDA, EMA, and NMPA drug approvals and form core recommendations across the National Comprehensive Cancer Network (NCCN), ESMO Clinical Practice Guidelines, and Chinese Society of Clinical Oncology (CSCO) lung cancer panels.
• Global Clinical Trial Innovation: As Principal Investigator for dozens of international and national multicenter studies, Prof. Wu offers qualifying patients direct access to next-generation bispecific antibodies, antibody-drug conjugates (ADCs), and novel molecular inhibitors years before commercial availability.

Guangdong Lung Cancer Institute (GLCI) Profile

Established as a premier specialized academic institution within Guangdong Provincial People's Hospital in Guangzhou, the Guangdong Lung Cancer Institute is internationally recognized as a center of clinical excellence. Integrating specialized thoracic surgical suites, dedicated inpatient clinical trial units, high-throughput molecular pathology platforms, and biobanking facilities, GLCI delivers seamless multidisciplinary coordination and treats thousands of international and domestic patients annually.

Why International Patients Seek Care with Prof. Wu Yi-Long

• The Definitive Authority in Precision Oncology: When facing rare mutations, unusual molecular co-alterations, or complex resistance pathways, consulting the clinician who authored the seminal trials provides unmatched diagnostic clarity.
• Evidence-Based Sparing of Overtreatment: Leveraging advanced MRD technologies and individualized "drug holiday" protocols, Prof. Wu ensures patients receive exactly the right amount of therapy without unnecessary toxicity.
• Access to Tomorrow's Therapeutics Today: Through GLCI's extensive clinical research network, patients with limited standard therapeutic alternatives can enter cutting-edge global clinical trials.
• World-Class Quality with Exceptional Efficiency: Comprehensive genetic re-evaluations, high-resolution imaging, and expert MDT treatment decisions are coordinated within days.

The Patient Journey: Navigating Care with CMCS

China Medical Concierge – Shanghai (CMCS) provides overseas patients with direct, streamlined access to Prof. Wu Yi-Long and the medical teams at Guangdong Lung Cancer Institute in Guangzhou:

• Step 1: Genomic & Clinical Dossier Review: Patients securely transmit complete medical histories, previous treatment timelines, NGS genetic sequencing panels, and DICOM imaging scans for preliminary evaluation.
• Step 2: Multidisciplinary Treatment Strategy & Trial Matching: CMCS coordinates an initial specialist case assessment to evaluate whether target reassessment, MRD blood testing, or clinical trial screening is appropriate.
• Step 3: Medical Visa, Transit & Accommodations: We issue medical visa invitation documentation, arrange meet-and-greet transit upon arrival in Guangzhou, and coordinate comfortable executive lodging near GDPH.
• Step 4: Dedicated Bilingual Medical Liaison: An experienced medical interpreter accompanies you through outpatient consultations, laboratory sampling, imaging diagnostics, and pharmacy dispensations.
• Step 5: Ongoing Remote Monitoring & Continuity of Care: Following your consultation and treatment initiation, CMCS coordinates long-term tracking of follow-up blood tests, imaging results, and periodic physician reviews.

Frequently Asked Questions

What are considered rare lung cancer driver mutations?

Rare mutations account for 1% to 3% of NSCLC cases each and include RET fusions, MET amplification/exon 14 skipping, HER2 mutations, ROS1 rearrangements, BRAF V600E, and NTRK fusions. Prof. Wu is a recognized global pioneer in targeted inhibitors designed specifically for these genomic subsets.

How does Minimal Residual Disease (MRD) testing guide treatment?

MRD testing detects microscopic traces of circulating tumor DNA (ctDNA) in the bloodstream following surgery. A persistent negative MRD result indicates a very low risk of recurrence, potentially allowing patients to avoid toxic adjuvant chemotherapy, while a positive result enables immediate targeted intervention before radiographic recurrence.

What is a "drug holiday" in targeted therapy?

For carefully selected patients with deep, sustained molecular responses, Prof. Wu pioneered structured breaks from targeted therapy under close ctDNA and radiographic monitoring. This approach prevents cumulative drug toxicity, restores organ function, and enhances quality of life without sacrificing oncological outcomes.

How long should international patients stay in Guangzhou for consultation?

A comprehensive consultation, repeat molecular blood work, and multidisciplinary treatment plan formulation usually require 3 to 5 business days in Guangzhou. If new targeted therapy initiation or clinical trial entry is planned, an initial stay of 1 to 2 weeks is recommended.

Schedule Your Consultation with Prof. Wu Yi-Long

If you or a loved one is seeking world-class expert consultation for lung cancer, rare driver mutations, targeted therapy resistance, or MRD monitoring, contact our medical concierge team today.

Contact CMCS Medical Concierge:

• Email: contract@medicalsh.com
• WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
• Website: www.medicalsh.com